Year: 2026
Type: article
Abstract: The new drug comments in Australian Prescriber are prepared by the editors and reviewed by subject matter experts.Some of the views expressed on newly approved products should be regarded as preliminary, as there may be limited published data at the time of publication, and little experience in Australia of their safety or efficacy.Before new drugs are prescribed, it is important that more detailed information is obtained from the approved product information, a medicines information centre or some other appropriate source.Report all suspected adverse reactions to new drugs to enable continued monitoring of their benefit-harm balance. New drugsDelgocitinib for chronic hand eczema Active ingredient: delgocitinib Brand name (sponsor): Anzupgo (Leo Pharma) Presentation: cream containing delgocitinib 20 mg/g in 15 g and 60 g tubes Route of administration: topical Approved indication: treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriateBackground: Hand eczema is a common inflammatory skin disease affecting the hands and wrists.It occurs in approximately 1 in 10 adults. 1 More than half of affected individuals develop chronic disease, defined as hand eczema persisting for more than 3 months or recurring twice or more within a year. 2 People with chronic hand eczema experience itchy, painful, blistered or fissured skin, which often interferes with daily activities and impairs quality of life.
Source: Australian Prescriber
Author: /
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7219568834